Limits...
Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review

View Article: PubMed Central - PubMed

ABSTRACT

Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in eyelash trichomegaly and scalp hair in six cases of pulmonary adenocarcinoma patients that had been administered erlotinib. The symptoms of eyelash trichomegaly include curly, irregular, excessively long and brittle eyelashes, and alterations of scalp hair include curly or straight, brittle, fine or rigid, reduced growth rate and volume. Since these side effects does not substantially impact patient quality of life, no treatments were administered. These changes in eyelashes and scalp hair gradually disappeared after withdrawal of erlotinib.

No MeSH data available.


Related in: MedlinePlus

Eyelash trichomegaly and hair change in case 3. (A) Patient's eyelashes and eyebrows became curly and brittle and (B) his scalp hair became curly, grew at a slower rate and reduced in volume due to of hair loss during treatment with erlotinib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998076&req=5

f2-etm-0-0-3460: Eyelash trichomegaly and hair change in case 3. (A) Patient's eyelashes and eyebrows became curly and brittle and (B) his scalp hair became curly, grew at a slower rate and reduced in volume due to of hair loss during treatment with erlotinib.

Mentions: A 68-year-old male patient with a diagnosis of stage cT1bN2M1b lung adenocarcinoma primarily located in the right upper lobe of the lung, metastasis to mediastinal lymph nodes, pleural membrane and bone had EGFR mutations at exon 21 of EGFR [c.2573T>G (p.L858R)] detected by direct Sanger sequencing test. As second line therapy, the patient received erlotinib (150 mg, daily) from March 22, 2011. All lesions reduced or disappeared gradually. His disease remained stable as of December 22, 2014 (45 months of erlotinib). During the treatment, he experienced slight skin rashes on his face. His eyelashes and eyebrows became curly and brittle after 3 months of treatment with erlotinib (Fig. 2). Additionally, his scalp hair became curly, grew at a slower rate and reduced in volume (Fig. 2) due to hair loss. Since these side effects did not influence the patient's life quality, no treatment was performed.


Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
Eyelash trichomegaly and hair change in case 3. (A) Patient's eyelashes and eyebrows became curly and brittle and (B) his scalp hair became curly, grew at a slower rate and reduced in volume due to of hair loss during treatment with erlotinib.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998076&req=5

f2-etm-0-0-3460: Eyelash trichomegaly and hair change in case 3. (A) Patient's eyelashes and eyebrows became curly and brittle and (B) his scalp hair became curly, grew at a slower rate and reduced in volume due to of hair loss during treatment with erlotinib.
Mentions: A 68-year-old male patient with a diagnosis of stage cT1bN2M1b lung adenocarcinoma primarily located in the right upper lobe of the lung, metastasis to mediastinal lymph nodes, pleural membrane and bone had EGFR mutations at exon 21 of EGFR [c.2573T>G (p.L858R)] detected by direct Sanger sequencing test. As second line therapy, the patient received erlotinib (150 mg, daily) from March 22, 2011. All lesions reduced or disappeared gradually. His disease remained stable as of December 22, 2014 (45 months of erlotinib). During the treatment, he experienced slight skin rashes on his face. His eyelashes and eyebrows became curly and brittle after 3 months of treatment with erlotinib (Fig. 2). Additionally, his scalp hair became curly, grew at a slower rate and reduced in volume (Fig. 2) due to hair loss. Since these side effects did not influence the patient's life quality, no treatment was performed.

View Article: PubMed Central - PubMed

ABSTRACT

Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in eyelash trichomegaly and scalp hair in six cases of pulmonary adenocarcinoma patients that had been administered erlotinib. The symptoms of eyelash trichomegaly include curly, irregular, excessively long and brittle eyelashes, and alterations of scalp hair include curly or straight, brittle, fine or rigid, reduced growth rate and volume. Since these side effects does not substantially impact patient quality of life, no treatments were administered. These changes in eyelashes and scalp hair gradually disappeared after withdrawal of erlotinib.

No MeSH data available.


Related in: MedlinePlus